TrAVeRse: A phase 2 trial of acalabrutinib, venetoclax and rituximab in patients with untreated mantle cell lymphoma

This trial is testing the medications acalabrutinib, venetoclax and rituximab (AVR) in adults with untreated mantle cell lymphoma (MCL).

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05951959

Trial aim and background  

There is currently no superior treatment regimen or curative option for patients with MCL. This trial aims to find out how effective the chemotherapy free triplet combination AVR is in patients with mantle cell lymphoma which has not previously been treated. 

Participants in the trial will receive 13 cycles of AVR induction, each lasting 28 days. All participants who complete all 13 cycles will be tested for a complete response, and will have a further cycle whilst waiting for this result. Participants who achieve a complete response will continue to receive acalabrutinib.

Who can enter 

Adults with MCL of stage II, III or IV which requires treatment may be eligible for this trial. 

Locations 

Recruitment is currently taking place in the following UK locations:

  • Norwich
  • Plymouth

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/study/NCT05951959

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.